![]() ![]() We are analysing this in our upcoming Phase 2 study to determine the potential as a non-invasive biomarker. ![]() Our precision medicine approach will leverage the detection of raised MPO levels in blood and sputum. MPO is an enzyme that leads to inflammation-induced tissue damage and disease exacerbations. This precision medicine approach will help us identify potential novel targets for life-changing medicines.” Ken Grime, Executive Director and Head of Bioscience COPD, AstraZeneca.īy targeting disease drivers of COPD, such as oxidative stress, cell senescence, chronic inflammation and fibrosis, we aim to develop precision medicines focused on disease modification so as to slow and stop disease progression.Ī newer area of interest is the key upstream mediator of oxidative stress, myeloperoxidase (MPO). 2 To address this, we are dissecting the 500+ abnormally expressed genes and defining their role in disease. “In chronic obstructive pulmonary disease (COPD) we have seen little innovation in decades despite it being the third leading cause of death world-wide. In the future, our ambition is to provide tailored treatments based on individual disease, or patient, categories determined by molecular disease drivers.Ĭhronic obstructive pulmonary disorder (COPD) We are now looking to identify urinary biomarkers which could be used to identify patients’ molecular disease classes non-invasively, allowing us greater precision when aligning the right patients to the right trials. For the first time, our research has shown that these disease categories based on molecular data are different from previous clinical classifications for CKD. Using unique datasets, the team has applied machine learning and artificial intelligence algorithms to classify patients into subclasses. Our aim is to close this gap, by uncovering the underlying genetic and molecular drivers of disease to identify the right treatment for the right patient.” Pernille Laerkegaard Hansen, Executive Director and Head of Bioscience Renal, AstraZeneca. The current symptom-based approach ignores the different underlying mechanisms. “Chronic Kidney Disease (CKD) encompasses various primary disorders and stages of progression, and the patient population is highly heterogenous. To improve patient outcomes, we must move beyond the current standard of care in which many patients are treated the same (a ‘one-size-fits-all’ approach) and sequentially across the disease pathway, and towards the possibility of targeting treatments to specific and earlier disease states. It is for these reasons that chronic obstructive pulmonary disease and chronic kidney disease have seen little innovation in decades and there are no approved treatments for the metabolic disorder non-alcoholic steatohepatitis. Currently, diagnosis relies on clinical symptoms and standard biomarkers – patient characteristics such as a gene, molecule, or other (e.g., blood pressure) – however, tests are often limited, imprecise and late in disease progression. They are heterogenous from how they present over time with an array of different symptoms and co-morbidities, to the way they are diagnosed over the course of disease. The challenge we face is that chronic diseases are biologically complex and driven by multiple mechanisms. Partnerships, alliances and recognitionĬhronic diseases affect billions of people worldwide and numbers are expected to rise considerably in future years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |